4D Molecular Therapeutics Posts $3.05M Q1 Revenue, Initiates Two Phase 3 Trials for Gene Therapies
FDMT has more than doubled off its 52-week low of $3.
Summary
4D Molecular Therapeutics reported Q1 2026 revenue of $3.05 million, a significant increase from the prior year, primarily driven by its collaboration with Otsuka Pharmaceutical. Despite the revenue growth, the company's net loss widened to $68.76 million, resulting in an EPS of $(1.01). Operationally, the company initiated two Phase 3 trials for its lead candidate 4D-150 and reported positive long-term Phase 1/2 data, while also implementing a 25% workforce reduction to align resources. This 10-Q filing provides crucial updates on the financial impact of the Otsuka collaboration and the advancement of key clinical programs, which are vital for a small-cap biotech. The company maintains a strong liquidity position with approximately $457.6 million in cash, providing a substantial runway for ongoing clinical development. Traders will be watching for continued progress in the Phase 3 trials and further updates on the company's pipeline.
At the time of this announcement, FDMT was trading at $9.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $519.1M. The 52-week trading range was $3.00 to $12.34. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.